대표어
한국학술지인용색인(NRF)
권호기사보기
| 기사명 | 저자명 | 페이지 | 원문 | 기사목차 |
|---|
국회도서관 홈으로
정보검색
소장정보 검색
결과 내 검색
동의어 포함
목차보기
Contents
Comparing Effectiveness Rituximab (Mabthera^®^) to Other Second-line Biologics for Rheumatoid Arthritis Treatment in Patients Refractory to or Intolerant of First-line Anti-tumor Necrosis Factor Agent : An Observational Study / Yong-Wook Park ; Ki-Jo Kim ; Hyung-In Yang ; Bo Young Yoon ; Sang Hyon Kim ; Seong-Ho Kim ; Jinseok Kim ; Ji Seon Oh ; Wan-Uk Kim ; Yeon-Ah Lee ; Jung-Yoon Choe ; Min-Chan Park ; Sang-Heon Lee 1
[요약] 1
INTRODUCTION 1
MATERIALS AND METHODS 2
RESULTS 4
DISCUSSION 6
CONCLUSION 8
REFERENCES 8
권호기사
참고문헌 (25건) : 자료제공( 네이버학술정보 )
| 번호 | 참고문헌 | 국회도서관 소장유무 |
|---|---|---|
| 1 | Epigenetics and autoimmunity. Overview.  |
미소장 |
| 2 | Korea Ministry of Health and Welfare and Korea Centers for Disease Control & Prevention. Korea Health Statistics 2009: Korea National Health and Nutrition Examination Survey (KNHANESIV-3). 2009, p. 557. | 미소장 |
| 3 | Rheumatoid arthritis: past, present and future |
미소장 |
| 4 | Characteristics of Korean Patients with RA: A Single Center Cohort Study | 소장 |
| 5 | 2009 National Health Insurance Statistical Yearbook. Seoul, Korea National Health Insurance Corporation, Health Insurance Review & Assessment Service, 2010, p. 472. | 미소장 |
| 6 | Guidelines for the management of rheumatoid arthritis: 2002 Update |
미소장 |
| 7 | Advances in the Medical Treatment of Rheumatoid Arthritis |
미소장 |
| 8 | Rheumatoid arthritis therapy after tumor necrosis factor and interleukin‐1 blockade |
미소장 |
| 9 | Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis |
미소장 |
| 10 | A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. |
미소장 |
| 11 | Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. |
미소장 |
| 12 | Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. |
미소장 |
| 13 | Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. |
미소장 |
| 14 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. |
미소장 |
| 15 | Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. |
미소장 |
| 16 | A Randomized, Pilot Study to Assess the Efficacy and Safety of Curcumin in Patients with Active Rheumatoid Arthritis |
미소장 |
| 17 | NICE technology appraisal guidance 195. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor:Part review of NICE technology appraisal guidance 36. Review of NICE technology appraisal guidance 126 and 141. August 2010. London, National Institute for Health and Clinical Excellence, 2010. | 미소장 |
| 18 | B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti–tumor necrosis factor agents |
미소장 |
| 19 | Finckh A, Ciurea A, Brulhart L, Möller B, Walker UA, Courvoisier D, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 2010; 69:387-93. | 미소장 |
| 20 | Prevalence and incidence of rheumatoid arthritis in South Korea. |
미소장 |
| 21 | Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. |
미소장 |
| 22 | Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. |
미소장 |
| 23 | Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period |
미소장 |
| 24 | Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy:a critical review. Arthritis Res Ther 2009; 11 Suppl 1:S1. | 미소장 |
| 25 | van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann RM, Furst DE, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013; 72:1496-502. | 미소장 |
MARC 보기
오류 데이터 정정요청
*표시는 필수 입력사항입니다.
알림톡 발송
| 전화번호 |
|---|
개인정보 수정 바로가기
연속간행물 권호 선택
우편복사 안내
- ◾ 도서관을 방문하지 못할 경우 인터넷, 팩스 등으로 자료 복사를 신청하고, 복사물을 우편·팩스 등으로 제공받는 서비스
- ◾ 대상자료: 일반도서, 연속간행물 및 학위논문
- ※ 고서, 고잡지, 훼손될 우려가 있는 자료, 마이크로폼 자료 및 신문 등 제외
- ◾ 신청 책수: 1인 5책 이하(1일 기준)
- ◾ 신청 절차: 자료 검색 → 우편복사 목록담기 → 복사 범위 입력 → 우편복사 주문서 입력 → 접수 및 확인
- ※ 저작권법에 의거하여 부분 복사(전체 페이지 수의 1/3 범위 이내)만 가능
- ◾ 복사 범위 입력 예시: (연속 페이지) 1-30, (부분 페이지) 25, 30-40
| 번호 | 발행일자 | 권호명 | 제본정보 | 자료실 | 원문 | 신청 페이지 |
|---|
도서위치안내(서울관)
도서위치안내: 정기간행물실(524호) / 서가번호: 국내17
2021년 이전 정기간행물은 온라인 신청(원문 구축 자료는 원문 이용)
0
확인
우편복사 목록담기를 완료하였습니다.
내서재에 담기
새로운 서재
*표시는 필수 입력사항입니다.
저장
저장 되었습니다.